Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/11/22
End: 10/31/24
Due: 10/31/25
Phase: N/A
Priority: Normal
Start: 01/11/22
End: 06/30/26
Due: 06/30/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| CT to Assess the Efficacy and Safety of Adding GMA to Infliximab in Paediatric Patients With Steroid-refractory Ulcerative Colitis | NCT05430412 | Adacyte Therapeutics SL | user2@example.com | None | 2022-01-11 | 2024-10-31 | 2025-10-31 | - | - | 2025-07-14 |
| National GMA Post-market Clinical Follow-up Study (GRACE) | NCT05636709 | Adacyte Therapeutics SL | user2@example.com | None | 2022-01-11 | 2026-06-30 | 2027-06-30 | - | - | 2025-07-14 |